The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial

Pouchelon, Jean‐Louis

doi:10.1016/s1760-2734(06)70025-x

Cited by 112 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, breed of dog, advanced age, and body weight (BW) � 20 kg, as well as degree of mitral valve pathology; left atrial (LA) and left ventricular (LV) dilation and dysfunction; increased LA pressure; right ventricular dysfunction; development of atrial fibrillation (AF) and pulmonary hypertension (PH); and increased concentration of circulating cardiac biomarkers (e.g., NT-pro-BNP) have been associated with a worse prognosis [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. On the contrary, use of several drugs, including ACE-inhibitors, pimobendan, and spironolactone has a proven positive effect both on the quality and duration of life in dogs with MMVD [19][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

Effect of temperature variation on hospital admissions and outcomes in dogs with myxomatous mitral valve disease and new onset pulmonary edema

et al. 2020

View full text Add to dashboard Cite

The effect of seasonal variation on hospital admissions and outcomes in humans with cardiovascular disease and congestive heart failure (CHF) has been described. This study evaluates the effect of temperature variation on admissions and outcomes in dogs with myxomatous mitral valve disease (MMVD) and first onset CHF. Ninety-three client-owned dogs with MMVD and a first occurrence of pulmonary edema were included in this retrospective clinical cohort study. Recorded clinical and echocardiographic variables were accumulated and analyzed with dogs allocated into groups in a temperature-wise manner that considered the mean of the average (Tave) and maximum ambient temperature (Tmax) of the 14 days preceding hospital admission. A survival analysis was also performed. No difference was found in the percentage of dogs decompensating in three different temperature periods (i.e., cold, intermediate, and hot temperature) according to both Tave and Tmax. Dogs developing CHF during the intermediate temperatures according to Tmax died earlier from cardiacrelated causes (median survival time 280 days, 95% CI = 147-486 days) compared to those decompensating during hot temperatures (median survival time 518 days, 95% CI = 344-819 days, P = 0.039). However, an effect of the ambient temperature on survival was not confirmed by Cox proportional hazard analysis. In conclusion, this study failed to show that ambient temperature has an effect on the first occurrence of CHF and outcomes in dogs with MMVD.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of temperature variation on hospital admissions and outcomes in dogs with myxomatous mitral valve disease and new onset pulmonary edema

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The efficacy of the therapy of CHF in dogs affected by spontaneous MMVD was evaluated, and the published studies were more numerous than in the previous twenty years. Many of the studies tested the effect and the efficacy of ACE inhibitors (captopril, enalapril, quinapril, ramipril, and benazepril), and over these ten years, they were introduced in the standard therapy of chronic CHF in dogs affected by MMVD [ 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 ]. In particular, it is important to mention the COVE study [ 147 ], the IMPROVE study [ 148 ], the BENCH study [ 156 ], and the LIVE study [ 155 ], which significantly contributed to the evaluation of the efficacy and effect of enalapril and benazepril.…”

Section: Resultsmentioning

confidence: 99%

“…Many of the studies tested the effect and the efficacy of ACE inhibitors (captopril, enalapril, quinapril, ramipril, and benazepril), and over these ten years, they were introduced in the standard therapy of chronic CHF in dogs affected by MMVD [ 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 ]. In particular, it is important to mention the COVE study [ 147 ], the IMPROVE study [ 148 ], the BENCH study [ 156 ], and the LIVE study [ 155 ], which significantly contributed to the evaluation of the efficacy and effect of enalapril and benazepril. The ACE inhibitors were administered at different dosages: benazepril from a minimum of 0.25 mg/kg once daily, captopril 0.5 mg/kg three times daily, quinapril 0.5 mg/kg once daily, enalapril from 0.38 mg/kg twice daily to 0.5 mg/kg once or twice daily, and ramipril 0.125 mg/kg once or twice daily.…”

Section: Resultsmentioning

confidence: 99%

Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020

Bagardi

Zamboni

Locatelli

et al. 2022

Animals

View full text Add to dashboard Cite

The treatment of chronic congestive heart failure (CHF), secondary to myxomatous mitral valve disease (MMVD) in dogs, has considerably changed in the last fifty years. An analysis of the literature concerning the therapy of chronic CHF in dogs affected by MMVD is not available, and it is needed. Narrative reviews (NRs) are aimed at identifying and summarizing what has been previously published, avoiding duplications, and seeking new study areas that have not yet been addressed. The most accessible open-access databases, PubMed, Embase, and Google Scholar, were chosen, and the searching time frame was set in five decades, from 1970 to 2020. The 384 selected studies were classified into categories depending on the aim of the study, the population target, the pathogenesis of MMVD (natural/induced), and the resulting CHF. Over the years, the types of studies have increased considerably in veterinary medicine. In particular, there have been 43 (24.29%) clinical trials, 41 (23.16%) randomized controlled trials, 10 (5.65%) cross-over trials, 40 (22.60%) reviews, 5 (2.82%) comparative studies, 17 (9.60%) case-control studies, 2 (1.13%) cohort studies, 2 (1.13%) experimental studies, 2 (1.13%) questionnaires, 6 (3.40%) case-reports, 7 (3.95%) retrospective studies, and 2 (1.13%) guidelines. The experimental studies on dogs with an induced form of the disease were less numerous (49–27.68%) than the studies on dogs affected by spontaneous MMVD (128–72.32%). The therapy of chronic CHF in dogs has considerably changed in the last fifty years: in the last century, some of the currently prescribed drugs did not exist yet, while others had different indications.

show abstract

“…The other drugs did not show any influence on the survival time in the multivariate analysis. Previous reports have indicated the effectiveness of ACEIs as a medical treatment for MMVD [ 2 , 11 ], and the guidelines for diagnosis and treatment of canine chronic valvular heart disease recommend the use of diuretics and ACEIs in the treatment of CHF [ 1 ]. At present, these medications make up the standard drug treatment regimen for dogs with CHF.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure

Mizuno

Yamano

Chimura³

et al. 2017

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD). Records of 197 client-owned dogs from 14 veterinary hospitals were included in this study. Dogs were administered conventional treatments with or without pimobendan. Sixty-four dogs received a standard dose of pimobendan (0.20–0.48 mg/kg every 12 hr (q12hr)), 49 dogs received a low dose of pimobendan (0.05–0.19 mg/kg q12hr), and 84 dogs received conventional therapy alone. Dogs in the standard-dose and low-dose pimobendan groups had significantly longer median survival times than dogs in the conventional group (334, 277 and 136 days, respectively; P<0.001). The reoccurrence rate of pulmonary edema in the standard-dose group was significantly lower than in the low-dose and conventional groups (43%, 59% and 62%, respectively; P<0.05). Combination of pimobendan with a conventional treatment regimen significantly prolonged survival time after an initial episode of pulmonary edema in dogs with CHF caused by MMVD. There was no difference in survival between dogs administered standard and low doses of pimobendan, but pimobendan did prevent the reoccurrence of pulmonary edema in a dose-dependent manner.

show abstract

The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial

Abstract: Benazepril extended the useful life-span of dogs with ISACHC class II and III heart failure (due to CVD) and was well tolerated.

Cited by 112 publications

References 19 publications

Effect of temperature variation on hospital admissions and outcomes in dogs with myxomatous mitral valve disease and new onset pulmonary edema

Effect of temperature variation on hospital admissions and outcomes in dogs with myxomatous mitral valve disease and new onset pulmonary edema

Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020

Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure

Contact Info

Product

Resources

About